The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
10201825 |
2 |
Solid-phase synthesis of benzisothiazolones as serine protease inhibitors.![EBI](/images/logo_chembl.png) |
Bristol-Myers Squibb Pharmaceutical Research Institute |
26122211 |
3 |
Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate.![EBI](/images/logo_chembl.png) |
Tokyo University of Pharmacy and Life Sciences |
16644215 |
52 |
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.![EBI](/images/logo_chembl.png) |
Celera Genomics |
16554154 |
9 |
Development of activity-based probes for trypsin-family serine proteases.![EBI](/images/logo_chembl.png) |
Celera Genomics |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.![EBI](/images/logo_chembl.png) |
University of Florida |
12930148 |
41 |
Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.![EBI](/images/logo_chembl.png) |
Johnson & Johnson Pharmaceutical Research & Development |
15081015 |
91 |
Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.![EBI](/images/logo_chembl.png) |
The Bristol-Myers Squibb Pharmaceutical Research Institute |
16725321 |
13 |
Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.![EBI](/images/logo_chembl.png) |
Celera Genomics |
16714109 |
40 |
Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.![EBI](/images/logo_chembl.png) |
Celera |
16540315 |
23 |
Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.![EBI](/images/logo_chembl.png) |
Mochida Pharmaceutical |
15911249 |
29 |
Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.![EBI](/images/logo_chembl.png) |
Aventis Pharmaceuticals |
15745817 |
14 |
Combinatorial approaches towards the discovery of new tryptase inhibitors.![EBI](/images/logo_chembl.png) |
University of Barcelona |
15546728 |
15 |
Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.![EBI](/images/logo_chembl.png) |
Aventis Pharmaceuticals |
15341931 |
15 |
Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.![EBI](/images/logo_chembl.png) |
Aventis Pharmaceuticals |
15081014 |
35 |
Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.![EBI](/images/logo_chembl.png) |
The Bristol-Myers Squibb Pharmaceutical Research Institute |
14698147 |
60 |
Synthesis of potent and selective 2-azepanone inhibitors of human tryptase.![EBI](/images/logo_chembl.png) |
The Bristol-Myers Squibb Pharmaceutical Research Institute |
11959009 |
7 |
Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors.![EBI](/images/logo_chembl.png) |
Institut FüR Biochemie |
11527724 |
30 |
Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.![EBI](/images/logo_chembl.png) |
Axys Pharmaceuticals |
11425524 |
62 |
Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.![EBI](/images/logo_chembl.png) |
Axys Pharmaceuticals |
11055356 |
236 |
Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.![EBI](/images/logo_chembl.png) |
Axys Pharmaceuticals |
11055355 |
72 |
Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.![EBI](/images/logo_chembl.png) |
Axys Pharmaceuticals |
27563406 |
128 |
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.![EBI](/images/logo_chembl.png) |
Roche Pharma Research and Early Development |
10612586 |
34 |
Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors.![EBI](/images/logo_chembl.png) |
Yoshitomi Pharmaceutical Industries |
30995036 |
52 |
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.![EBI](/images/logo_chembl.png) |
Novartis Institutes For Biomedical Research |
9873535 |
13 |
Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics.![EBI](/images/logo_chembl.png) |
Molecumetics |